echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Mutual complaints, real-name reports... 10 drugs were processed!

    Mutual complaints, real-name reports... 10 drugs were processed!

    • Last Update: 2022-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 18, the official website of the Hunan Provincial Medical Insurance Bureau issued the "Notice on Price Correction and Price Restriction of Some Drugs", as well as a list of generic names of drugs, and decided to make a big difference in the prices of the same listings.
    ( In particular, 10 drugs, such as famotidine, which have been listed on the Internet for different periods of time, have obvious inconsistencies in price and quality, have many mutual complaints, and have been reported as inflated by their real names, have undergone price corrections and limited price listings
    .
    The day before, the Sichuan Provincial Medicine and Equipment Recruitment and Procurement Center also removed 186 products that concealed the national lowest listing price/bidding price (Tibet price)
    .
    Since last year, more and more regions have implemented monitoring of drug prices, and a new wave of price adjustments and withdrawals from the Internet is blowing across the country
    .
    Price correction and price limit listing will be normalized.
    For the price correction and price limit rules, Hunan requires three points: First, drugs that have been listed on the Hunan Provincial Pharmaceutical Centralized Purchasing Platform, and the listed price exceeds the lowest unit of the same generic name and the same medical insurance dosage form.
    If the price is 1.
    8 times the price, the excess part will be included in the listing price at 50%, and the lowest listing price and the actual minimum transaction price of other provincial platforms will be linked to the lowest price limit of the three
    .
    Different specifications are determined by conversion according to the price difference rule
    .
    Among them, if the comparable price of large-capacity injection units is not higher than 4.
    5 yuan, it will be linked to the lowest price limit of the national provincial platform and the actual lowest transaction price
    .
    Second, for the drugs of other companies under the same generic name that are not linked to the provincial procurement platform, the comparable price of the same generic name and the same medical insurance dosage form should not exceed 1.
    8 times the lowest unit price, and the lowest online price and actual minimum transaction linked to other provincial platforms Price, take the lowest value of the three and limit the price to hang on the net
    .
    The third is, after the price limit is listed according to the above rules, if there are two or more drugs listed on the net with the same generic name, the same medical insurance dosage form and the same specification, the minimum listed price is 1.
    8 times the limit price, and the drugs listed on the net with more than 1.
    8 times the limit price need to be listed on the net.
    Take the initiative to lower the listing price to no more than 1.
    8 times the limit price, or suspend its listing qualification
    .
    Among the 10 drugs, cerebrovascular disease drugs Piracetam and Ligustrazine injection are the largest varieties with over 1 billion
    .
    Among them, the leading enterprise of piracetam injection is Shandong Weigao
    .
    Both ranitidine and famotidine are representative drugs for the treatment of peptic ulcer, ranitidine is a second-generation H2 receptor antagonist, and famotidine is a third-generation H2 receptor antagonist
    .
    According to data from Minet.
    com, the terminal sales of famotidine in Chinese public medical institutions exceeded 500 million yuan in 2020, a year-on-year increase of 284.
    04%
    .
    Among them, injections account for more than 95%, and Jiangxi Gannan Haixin Pharmaceutical has a market share of nearly 24%
    .
    In recent years, the terminal sales of ranitidine injections in Chinese public medical institutions have grown rapidly, with a year-on-year increase of over 30% in 2019
    .
    In addition, in 2020, the terminal sales of dihyprophylline injection in Chinese public medical institutions will exceed 100 million yuan, and Jilin Jinsheng has the highest market share
    .
    However, the terminal sales of Citicoline Sodium Sodium Chloride Injection and Citicoline Sodium Glucose Injection used for acute craniocerebral trauma and disturbance of consciousness after brain surgery in 2020 did not exceed 100 million yuan in Chinese public medical institutions.
    Added new drugs to the 2021 version of the National Medical Insurance Catalogue, which is expected to be used in hospital terminals after entering the Medicaid Catalogue
    .
    It is understood that the implementation of drug price correction and price limit listing is an effective means to solve the falsely high drug prices and rectify the order of the pharmaceutical market
    .
    Hunan also stated that it will implement normalized management after gaining certain experience
    .
    Medical insurance departments at all levels should strengthen the daily supervision of drug purchase prices within their jurisdictions, and promptly report to the provincial bureau if abnormal prices and purchases are found
    .
    As the main body of drug purchase and use, each medical institution should standardize the behavior of drug purchase and sales, strictly implement the zero-difference rate of drugs, and select drugs with appropriate prices for purchase and use according to clinical drug needs
    .
    Drug manufacturers must consciously abide by price rules, operate with integrity, and ensure the quality and timely supply of drugs
    .
    If it is verified that there are dishonest acts such as collusion to manipulate market prices, omissions and concealment of price information, supply of medicines with substandard quality, and failure to deliver medicines in a timely manner, they will be dealt with in accordance with relevant regulations
    .
    186 drugs were withdrawn from the Internet for concealing the lowest price
    .
    According to a notice issued by the Sichuan Pharmaceutical Equipment Bidding and Procurement Service Center, 186 products that concealed the lowest online price/bidding price (Tibet price) were withdrawn from the Internet
    .
    The drugs withdrawn include lidocaine hydrochloride injection, ornidazole tablets, ribavirin tablets and other commonly used clinical western medicines, as well as Chinese patent medicines such as Niuhuangjiedu tablets and Banlangen granules
    .
    Previously, the Sichuan Provincial Pharmaceutical Equipment Tendering and Procurement Service Center issued the "Rectification Announcement", stating that on the basis of giving enterprises many opportunities for rectification, in order to maintain the seriousness of the provincial centralized procurement work, the center will compare the national database.
    Computer verification and manual review of drug product declarations
    .
    Any pharmaceutical company that conceals the lowest price in the country, is listed on the Internet with less than five provincial prices, or fails to complete the mapping between the original Sichuan serial number and the national medical insurance consumables code mapping, etc.
    , will be given credit ratings, suspended from the Internet, and withdrawn from the Internet
    .
    Not long ago, the Hubei Provincial Medical Insurance Bureau notified that it received complaints from the public that Nanjing Haijing Pharmaceutical Co.
    , Ltd.
    vitamin D2 soft capsules failed to actively declare the lowest price in the country in a timely manner, and was suspended from the Internet
    .
    It is understood that Hubei has established a trading suspension mechanism to suspend trading and cancel the listing on the Internet, and regularly clean up drugs that have no transactions, prices that are not adjusted according to regulations, and are not delivered in time, and gradually phase out drugs that do not meet clinical needs; network mechanism to restrict corporate behavior
    .
    Since last year, the provinces have carried out a large-scale withdrawal of drugs without purchase records, and the prices of drugs on the Internet have also been continuously adjusted
    .
    According to the "14th Five-Year Plan" for National Medical Security issued by the State Council, a mechanism for monitoring the purchase price of drugs and medical consumables in public medical institutions and a sharing mechanism for transaction price information will be established to improve the analysis of abnormal changes in the prices of drugs and medical consumables.
    Early warning response capability
    .
    Strengthen the normalized supervision of the prices of drugs and medical consumables, implement the national drug price monitoring project, fully implement the drug price and credit evaluation system for recruitment and procurement, and flexibly use cost surveys, letter inquiries and interviews, credit evaluation, information disclosure, price index, and online rules.
    and other management tools to curb the inflated prices of drugs and medical consumables, take into account the reasonable profits of enterprises, and promote the high-quality development of the pharmaceutical industry
    .
    It is expected that in the future, the means of drug price management in various places will be more abundant, and the strategies of "removing the Internet" and "limiting prices" will continue to be implemented
    .
    Hunan Price Correction and Price Restriction List of Generic Names of Drugs Listed on the Internet Serial Number Injections 7 Troxerutin Injections 8 Aminophylline Injections 9 Dihyprophylline Injections 10 Theophylline Sustained-Release Controlled-Release Formulations
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.